34 results on '"Schieferdecker, Aneta"'
Search Results
2. 48/w mit Erbrechen, Schwäche, Gewichtsverlust und Dyspnoe bei metastasiertem Magenkarzinom: Vorbereitung auf die Facharztprüfung: Fall 48
3. CD8+ CD28− regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III study
4. Correction: “Being an informal caregiver – strengthening resources”: mixed methods evaluation of a psychoeducational intervention supporting informal caregivers in palliative care
5. “Being an informal caregiver – strengthening resources”: mixed methods evaluation of a psychoeducational intervention supporting informal caregivers in palliative care
6. 74/w mit progredientem Leber- und Nierenversagen 8 Wochen nach Beendigung der onkologischen Therapie eines metastasierten Pankreaskarzinoms: Vorbereitung auf die Facharztprüfung: Fall 46
7. 74/m mit starken Schmerzen bei bekanntem metastasiertem Prostatakarzinom: Vorbereitung auf die Facharztprüfung. Fall 47
8. Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial
9. Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial
10. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial
11. CD8+CD28−regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III study
12. A transplant “immunome” screening platform defines a targetable epitope fingerprint of multiple myeloma
13. Comparison of three different serum-free light-chain assays—implications on diagnostic and therapeutic monitoring of multiple myeloma
14. 74/m mit starken Schmerzen bei bekanntem metastasiertem Prostatakarzinom
15. Long-Term Outcome of a Prospective Randomized Trial Comparing Continuous Lenalidomide/Dexamethasone with Lenalidomide/Dexamethasone Induction, MEL140 with Autologous Blood Stem Cell Transplantation and Single Agent Lenalidomide Maintenance in Patients of Age 60-75 Years with Newly Diagnosed Multiple Myeloma
16. Elotuzumab in Combination with Lenalidomide, Bortezomib, Dexamethasone and Autologous Transplantation for Newly-Diagnosed Multiple Myeloma: Results from the Randomized Phase III GMMG-HD6 Trial
17. Multidimensional scaling analysis identifies pathological and prognostically relevant profiles of circulating T-cells in chronic lymphocytic leukemia
18. Immunological Subgroups Predicting Efficacy of Elotuzumab in Multiple Myeloma Patients: Insights from the GMMG-HD6 Clinical Trial
19. Leitlinie : Empfehlungen der Fachgesellschaft zur Diagnostik und Therapie h��matologischer und onkologischer Erkrankungen
20. Comparison of three different assays demonstrates heterogeneity in determination of serum free light chains - implications on diagnostic and therapeutic monitoring of multiple myeloma
21. Prospective monitoring of immune signatures in newly diagnosed high risk multiple myeloma patients under treatment with Isatuximab, Carfilzomib, Lenalidomide and Dexamethasone (I-KRd): First results of the GMMG-CONCEPT trial
22. Isatuximab, Carfilzomib, Lenalidomide and Dexamethasone (I-KRd) in front-line treatment of high-risk Multiple Myeloma: Results of the Safety Run-In cohort in the phase II, multicenter GMMG-CONCEPT trial
23. Monoklonale Gammopathie unklarer Signifikanz – ein häufiger Nebenbefund
24. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial
25. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial
26. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial
27. Potent in vitro and in vivo effects of polyclonal anti-human-myeloma globulins
28. Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma
29. Epidermal growth factor receptor mutations may confer resistance or cross-resistance to cetuximab and panitumumab and can be detected in circulating tumor DNA.
30. Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer
31. Severe and irreversible myelopathy after concurrent systemic and intrathecal nucleoside analogue treatment for refractory diffuse large B-cell lymphoma: A case report and review of the literature
32. Denosumab mimics the natural decoy receptor osteoprotegerin by interacting with its major binding site on RANKL
33. Severe and irreversible myelopathy after concurrent systemic and intrathecal nucleoside analogue treatment for refractory diffuse large B-cell lymphoma: A case report and review of the literature.
34. [Monoclonal Gammopathy Of Unknown Significance - A Common Incidental Finding - What is to be thought of? What has to be done?]
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.